Viridian Therapeutics Inc... (VRDN)
NASDAQ: VRDN
· Real-Time Price · USD
23.01
0.74 (3.32%)
At close: Oct 16, 2025, 3:59 PM
23.31
1.30%
After-hours: Oct 16, 2025, 07:39 PM EDT
3.32% (1D)
| Bid | 22.97 |
| Market Cap | 1.88B |
| Revenue (ttm) | 305K |
| Net Income (ttm) | -344.06M |
| EPS (ttm) | -3.57 |
| PE Ratio (ttm) | -6.45 |
| Forward PE | -5.14 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 23.12 |
| Volume | 1,506,792 |
| Avg. Volume (20D) | 787,504 |
| Open | 22.46 |
| Previous Close | 22.27 |
| Day's Range | 21.78 - 23.06 |
| 52-Week Range | 9.90 - 27.20 |
| Beta | 0.54 |
| Ex-Dividend Date | n/a |
About VRDN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VRDN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VRDN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsViridian Therapeutics Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+6.02%
Viridian Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
4 months ago
+7.8%
Viridian Therapeutics shares are trading higher after the company announced positive long-term durability data from its THRIVE Phase 3 clinical trial of veligrotug in TED patients.
2 weeks ago · seekingalpha.com
Viridian Therapeutics: De-Risked Leadership In Thyroid Eye DiseaseViridian Therapeutics (VRDN) offers a differentiated next-gen therapy for Thyroid Eye Disease, targeting a large, underpenetrated market dominated by Amgen's Tepezza. VRDN-001 (veligrotug) demonstrate...
2 months ago · fool.com
Viridian (VRDN) Q2 Net Loss Widens 55%Viridian (VRDN) Q2 Net Loss Widens 55%
